Search from website

Science

Publications

Discover Icosagen’s scientific publications showcasing research and innovation across biotechnology, life sciences, and pharmaceutical development.

Our HybriFree Technology is based on B-cell cloning and used for efficient discovery of monoclonal antibodies from immunized chickens and rabbits, ready for their immediate production in mammalian cells. HybriFree antibody discovery is rapid, flexible and effective. It can also be used for cloning antibodies from recovered patients’ PBMCs or from existing hybridomas.

QMCF Technology

Our QMCF Technology is a proprietary, fast, and reliable transient mammalian expression system for recombinant protein production with high yields of up to 1g/L. QMCF-made recombinant proteins are suitable for pre-clinical in vivo & in vitro studies, structural biology, drug discovery and as well as for commercial diagnostic assays.

IcoCell® Technology

IcoCell® is a proprietary platform to efficiently generate CHO-based stable high producer cell lines. These serve for large-scale GMP-compliant production of therapeutic recombinant proteins and monoclonal antibodies, both for clinical trial materials as well as for commercial production afterwards.

HPV assay

Icosagen has developed a specific 3D cell-based assay to identify human papillomavirus (HPV) DNA replication inhibitors in high-throughput format. In a proof of concept (PoC) study, 5 high-risk HPV specific inhibitors were identified that influence Tdp1 dependent DNA repair.

EU projects and R&D Collaboration

Icosagen participates in several international and national research programmes and projects.

Buy catalog products

Icosagen Diagnostic offers recombinant antibodies and antigens for diagnostic companies, as well as for research use. Pharma-grade reagents produced solely by Icosagen in the European Union, are now sold as off-the-shelf products.

Latest news

Publication: New 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗗𝗡𝗔 𝗥𝗲𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 – 𝗔 𝗖𝗼𝗻𝘀𝗲𝗿𝘃𝗲𝗱 𝗣𝗵𝗼𝘀𝗽𝗵𝗼𝗿𝘆𝗹𝗮𝘁𝗶𝗼𝗻 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 Controls 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗖𝗠𝗚 𝗛𝗲𝗹𝗶𝗰𝗮𝘀𝗲 could Lead to New Therapeutics

02.04

Important Alert: Fraudulent Job Offers

07.03

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070